NBE-THERAPEUTICS
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
NBE-THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2012-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nbe-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+41616332230
Email Addresses:
[email protected]
Total Funding:
65.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Nginx Google Maps Microsoft Azure DNS Google Maps API
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
INNOVO by Atlantic Therapeutics
INNOVO by Atlantic Therapeutics is a medical technology firm that develops pelvic floor muscle strengthening and nerve stimulation products.
BioPheresis
BioPheresis Technologies, a biotech company based in Heidelberg, Germany, offers a blood treatment system designed for cancer cure.
Calcivis
Calcivis is a biotech company that focuses on unmet needs in dentistry.
Precirix
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CellCentric
CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.
Centauri Therapeutics
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
Chao Ju Ophthalmology
Chao Ju Ophthalmology is an ophthalmology treatment firm.
Combat Medical
Combat Medical are a Spanish company that have developed a new treatment for bladder cancer, and are planning to start the business in the
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Faeth Therapeutics
Faeth Therapeutics is a cancer metabolism company that focuses on nutrition treatments for cancer patients.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Gelmetix
Gelmetix is a medical device company developing a polymer treatment for chronic lower-back pain.
Hox Therapeutics
HOX Therapeutics Ltd is a spin-off from the University of Surrey Oncology Department
INOFEA
INOFEA AG is a biotech company that offers a platform technology capable to fit enzymes in vivo and process conditions.
INSERM
Inserm is a medical research institute focusing on the development of the treatment for diseases affecting all body systems.
Barricaid
Barricaid develops a bone-anchored implant designed to close large defects in the annulus.
Ixico
Ixico is a U.K.-based company that provides clinical trial services worldwide.
MediGene
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Oncomark
OncoMark is an Irish diagnostics company dedicated to develop superior tests for cancer patient stratification.
Retina Implant
Retina Implant is a biotech company which develops subretinal implants for partially sighted and blind patients.
ReViral
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
River BioMedics
River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing.
SANIFIT
SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.
Sapiens Steering Brain Stimulation
Sapiens is a medical device company that delivers solutions for deep brain stimulation therapy.
SciBase
SciBase is a medical technology company that develops devices for detection of malignant melanoma.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Spear Therapeutics
Spear Therapeutics is a privately held company that develops prodrugs for the treatment of cancer.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Boehringer Ingelheim
Boehringer Ingelheim investment in Series C - NBE-Therapeutics
PPF Group
PPF Group investment in Series C - NBE-Therapeutics
PPF Group
PPF Group investment in Series B - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - NBE-Therapeutics
Novo Holdings
Novo Holdings investment in Series B - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - NBE-Therapeutics
PPF Group
PPF Group investment in Series B - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - NBE-Therapeutics
Newest Events participated
Participated in Swiss Startup Day
on 2015-10-21 as exhibitor
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-03 | NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer |
Official Site Inspections
http://www.nbe-therapeutics.com
- Host name: mc24r1511.dnh.net
- IP address: 81.173.83.107
- Location: Zurich Switzerland
- Latitude: 47.3664
- Longitude: 8.5546
- Timezone: Europe/Zurich
- Postal: 8005
More informations about "NBE-Therapeutics"
Overview - NBE Therapeutics
NBE-Therapeutics is a privately-owned biotech company founded in 2012 and located in Basel, Switzerland. In December 2020 NBE-Therapeutics was acquired by Germany based private …See details»
NBE-Therapeutics - Crunchbase Company Profile & Funding
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the …See details»
New NBE Therapeutics antibody-drug conjugate R&D center
17 hours ago NBE Therapeutics, a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company’s oncology research …See details»
BI to Acquire NBE-Therapeutics | Boehringer Ingelheim US
About NBE-Therapeutics NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory …See details»
NBE Therapeutics - The Org
NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo …See details»
NBE-Therapeutics - Funding, Financials, Valuation & Investors
NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
NBE-Therapeutics AG – Swiss Biotech
NBE-Therapeutics engages in the development of “next-generation”, antibody drug conjugates (ADCs) with the objective to develop first-in-class ADC product candidates until clinical proof …See details»
NBE-Therapeutics Company Profile | Management and Employees …
NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug …See details»
Leadership - NBE Therapeutics
Sie erreichen damit Internetseiten, die nicht von NBE-Therapeutics AG erstellt wurden und auf die NBE-Therapeutics AG keinen Einfluss hat. Wir können daher keine Garantie für Inhalt und die …See details»
Boehringer Ingelheim strengthens antibody-drug conjugate …
10 hours ago CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of …See details»
NBE Therapeutics - VentureRadar
NBE Therapeutics GmbH is a Basel, Switzerland, based privately held biotechnology company dedicated to the discovery and development of innovative antibody based drugs, with an initial …See details»
NBE Therapeutics 2025 Company Profile: Valuation, Investors ...
When was NBE Therapeutics founded? NBE Therapeutics was founded in 2012. Where is NBE Therapeutics headquartered? NBE Therapeutics is headquartered in Basel, Switzerland. What …See details»
Boehringer commits $31M to ADC R&D via NBE Therapeutics facility
7 hours ago The site in the European biotech hub of Basel, Switzerland, is run by Boehringer’s subsidiary NBE Therapeutics. Boehringer bought the Swiss biotech for $1.5 billion in 2020 in a …See details»
Agreement-to-acquire-NBE-Therapeutics - Boehringer Ingelheim
Dec 10, 2020 NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory …See details»
Boehringer to acquire NBE-Therapeutics for $1.43bn
Dec 11, 2020 With the acquisition, NBE-Therapeutics will work as a new site within Boehringer’s R&D network from its campus in Basel. NBE-Therapeutics CEO Bertrand Damour said: “We …See details»
Übernahme von NBE Therapeutics | Boehringer Ingelheim
Dec 10, 2020 Ingelheim, Deutschland und Basel, Schweiz – 10. Dezember 2020 – Boehringer Ingelheim gab heute die Unterzeichnung des Vertrags für die Übernahme aller Anteile an NBE …See details»
NBE-Therapeutics Company Profile - Office Locations ... - Craft
NBE-Therapeutics engages in the development of “next-generation” antibody drug conjugates (ADCs) leveraging its proprietary technology platforms for therapeutic antibody and site …See details»
Boehringer Ingelheim strengthens antibody-drug conjugate
8 hours ago Committed to scientific excellence and innovation, NBE Therapeutics is dedicated to revolutionizing the field of oncology therapeutics by providing precise and effective treatment …See details»
Acquisition agreement with Boehringer Ingelheim for NBE …
Dec 10, 2020 NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The …See details»
Boehringer Ingelheim strengthens antibody-drug conjugate
10 hours ago NBE Therapeutics focuses on developing next-generation ADCs, a targeted approach that delivers cancer-fighting agents directly to tumor cells while limiting effects on …See details»